The Prognostic Value of Systematic Genetic Screening in Amyotrophic Lateral Sclerosis Patients.

Di He,Yining Liu,Siqi Dong,Dongchao Shen,Xunzhe Yang,Meng Hao,Xianhong Yin,Xinyi He,Yi Li,Yi Wang,Mingsheng Liu,Jiucun Wang,Xiangjun Chen,Liying Cui
DOI: https://doi.org/10.1007/s00415-023-12079-1
2024-01-01
Journal of Neurology
Abstract:Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with complex genetic architecture. Emerging evidence has indicated comorbidity between ALS and autoimmune conditions, suggesting a potential shared genetic basis. The objective of this study is to assess the prognostic value of systematic screening for rare deleterious mutations in genes associated with ALS and aberrant inflammatory responses. A discovery cohort of 494 patients and a validation cohort of 69 patients were analyzed in this study, with population-matched healthy subjects (n = 4961) served as controls. Whole exome sequencing (WES) was performed to identify rare deleterious variants in 50 ALS genes and 1177 genes associated with abnormal inflammatory responses. Genotype–phenotype correlation was assessed, and an integrative prognostic model incorporating genetic and clinical factors was constructed. In the discovery cohort, 8.1
What problem does this paper attempt to address?